-
Copper prices fluctuate in a narrow range, and the short-term rebound is limited in height
Time of Update: 2022-12-06
Copper pricesIn terms of external trading, LME March copper opened slightly higher at $5728 in the morning, and once fell straight down to around $5696 after a narrow range, and then the price fluctuated and sorted, and the price rose straight in the afternoon, the highest rose to $5735, and fell back to the green before closing, and the Asian market closed at $5712.
-
Gansu strengthens the platform support of basic disciplines such as chemistry
Time of Update: 2022-11-25
Recently, the Department of Science and Technology of Gansu Province issued the "Guidelines for the Construction of Gansu Basic Discipline Research Center" (hereinafter referred to as the "Work Guidelines"), aiming to provide platform support for the development of basic disciplines such as chemistry and biology, attract and cultivate high-level leading talents, and condense and stabilize high-level research teams to concentrate on research and intellectual innovation.
-
Why Alzheimer's disease damages certain parts of the brain
Time of Update: 2022-11-25
Researchers at Washington University School of Medicine in St. Louis believe the similarities between the two sets of maps suggest that APOE played a role in making certain brain regions particularly vulnerable to Alzheimer's disease.
-
Issue 29/2013 - Daqing Petrochemical successfully developed automotive fuel tank material
Time of Update: 2022-11-12
(Gao Yuan) Daqing Petrochemical successfully developed automotive fuel tank materialRecently, Daqing Petrochemical Company successfully developed a new product of DMDA6045 polyethylene for automotive fuel tanks, marking the successful launch of the first batch of automotive fuel tank materials produced by new inorganic chromium-based catalysts and vapor phase fluidized bed process in China.
-
Issue 48, 2012 - Asahi Kasei Kawasaki Innovation Center completed
Time of Update: 2022-11-12
(Li Wei) Asahi Kasei Kawasaki Innovation Center completedAsahi Kasei Chemicals recently announced the official opening of its new integrated R&D center, the Kawasaki Innovation Center, located in Kawasaki, Kanagawa Prefecture, Japan, which opened on December 17, 2012.
-
ESMO2022 focuses on the therapeutic benefits of androgen receptor antagonists for mHSPC from a patient perspective
Time of Update: 2022-10-03
*For medical professionals onlyEffectively improving patients' disease symptoms and quality of life is also an important mission of anti-cancer treatment!Advanced prostate cancer can be divided into s
-
Evidence-Based Medicine is worth reading
Time of Update: 2022-09-09
Analysis conclusionBased on this SR, for AS protocols without MRI, the investigators recommend: (1) Low-risk patients with International Society of Urology Pathology Classification (ISUP) 2, or a single intermediate-risk factor (excluding ISUP 3) (2) Patients with low-risk but more extensive involvement (number of positive needles ≥ 3 or CI > 50%) PCa patients in ISUP grade 1 should be closely monitored, while similar patients in ISUP grade 2 should be closely monitored.
-
Can eating well prevent cancer
Time of Update: 2022-09-05
" The White Paper on Dietary Nutrition for Cancer Patients in China aims to change this situation.
" The White Paper on Dietary Nutrition for Cancer Patients in China aims to change this situation.
-
Qionglai City, Sichuan: Make every effort to build an innovative and characteristic town for the international seed industry
Time of Update: 2022-08-31
Qionglai City, Sichuan Province has further promoted the work of “Three Rural Areas”, focusing on the national food security strategy, seizing the opportunity of the national seed industry layout, fo
-
For this part of early breast cancer patients, adjuvant chemotherapy is useless
Time of Update: 2022-08-19
Multivariate Cox analysis was performed to investigate the effect of adjuvant chemotherapy on T1a, T1b and T1cN0M0 BC, including various tumor grades and four molecular subtypes .
-
BMC Cancer: Durvalumab treatment improves patient outcomes after chemoradiotherapy in locally advanced non-small cell lung cancer (LA-NSCLC
Time of Update: 2022-05-18
The purpose of this study is to evaluate the effect of durvalumab treatment on the prognosis of patients with locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy .
Taken together, studies have shown that durvalumab treatment following chemoradiotherapy in locally advanced non-small cell lung cancer (LA-NSCLC) improves patient outcomes .
-
It's time to eradicate
Time of Update: 2022-05-09
pylori eradication therapy on gastric cancer incidence and mortality in a high-risk population .
To assess the long-term effects of Helicobacter pylori eradication therapy on gastric cancer incidence and mortality in a high-risk population .
-
BMS Oral Kinase Inhibitor Inrebic Approved by UK NICE for Myelofibrosis
Time of Update: 2022-02-26
CompilenewbornThe UK National Institute for Health and Clinical Excellence (NICE) recently issued a final assessment decision (FAD) recommending the use of Bristol-Myers Squibb's oral kinase inhibitor Inrebic (fedratinib) in the NHS for the treatment of bone marrow Fibrosis, a rare blood cancer that affects the bone marrow and disrupts the production of blood cells in the body .
-
Prof. He Zhisong: Important Clinical Research on Urological Tumors in 2021
Time of Update: 2022-02-24
Subgroup analysis based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score shows progression-free survival (PFS) of pembrolizumab combined with axitinib in the low-risk group compared with sunitinib No significant benefit was achieved, but the intermediate and high risk group benefited; the low-risk group also did not achieve significant OS benefit, with 42-month OS rates of 72.
-
Int J Urol: The impact of platinum-based first-line chemotherapy on the overall survival of patients with metastatic urothelial carcinoma
Time of Update: 2021-11-02
Recently, researchers from Japan published an article in Int J Urol, investigating the effect of the number of cycles of chemotherapy and the objective response on the overall survival of patients with metastatic urinary tract cancer treated with pembrolizumab .
